Merck Company Profile

What is the competitive landscape for MERCK

MERCK has eighty-nine approved drugs.

There are eighteen US patents protecting MERCK drugs.

There are four hundred and one patent family members on MERCK drugs in fifty-six countries and one hundred and thirty-three supplementary protection certificates in twenty countries.

Summary for Merck

International Patents:	401
US Patents:	18
Tradenames:	75
Ingredients:	67
NDAs:	89
Patent Litigation for Merck:	See patent lawsuits for Merck
PTAB Cases with Merck as patent owner:	See PTAB cases with Merck as patent owner

Drugs and US Patents for Merck

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Kgaa	LEVOTHYROXINE SODIUM	levothyroxine sodium	TABLET;ORAL	076752-005	Jun 16, 2005		DISCN	No	No
Merck Kgaa	LEVOTHYROXINE SODIUM	levothyroxine sodium	TABLET;ORAL	076752-008	Jun 16, 2005		DISCN	No	No
Merck Kgaa	LEVOTHYROXINE SODIUM	levothyroxine sodium	TABLET;ORAL	076752-004	Jun 16, 2005		DISCN	No	No
Merck	ALDORIL 15	hydrochlorothiazide; methyldopa	TABLET;ORAL	013402-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Merck

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014	5,703,079
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-002	Oct 7, 2011	7,078,381
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001	5,767,097*PED
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001	6,472,373*PED

Paragraph IV (Patent) Challenges for MERCK drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	115 mg/vial		2012-01-25
	for Oral Suspension	125 mg/Kit		2016-11-23
	for Injection	200 mcg/vial		2015-05-01
	Oral Suspension	40 mg/mL		2011-02-28
	Injection	18 mg/mL, 16.7 mL vials		2015-11-24
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-19
	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg		2012-11-06
	For Injection	50 mg/vial and 70 mg/vial		2009-06-26
	Capsule	40 mg, 80 mg and 125 mg		2008-11-03
	Injection	150 mg/vial		2012-01-25
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	Capsules	140 mg and 180 mg		2008-03-24
	Delayed-release Tablets	100 mg		2014-06-16
	Tablets	25 mg, 50 mg and 100 mg		2010-10-18
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-25
	Oral Solution	70 mg/75 mL		2007-09-07

International Patents for Merck Drugs

Country	Patent Number	Estimated Expiration
South Korea	101350420
Tunisia	2014000345
South Africa	201405949
Croatia	P20211686

Supplementary Protection Certificates for Merck Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2666774	PA2020518,C2666774-2	Lithuania		PRODUCT NAME: RELEBAKTAMAS, PASIRINKTINAI MONOHIDRATO PAVIDALU, SU IMIPENEMU IR CILASTATINU, PASIRINKTINAI NATRIO DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/19/1420 20200213
2666774	31/2020	Austria		PRODUCT NAME: RELEBACTAM, GEGEBENENFALLS IN DER FORM DES MONOHYDRATS, IMIPENEM UND CILASTATIN, GEGEBENENFALLS IN DER FORM DES NATRIUMSALZES.; REGISTRATION NO/DATE: EU/1/19/1420 (MITTEILUNG) 20200217
2666774	C202030035	Spain		PRODUCT NAME: RELEBACTAM, OPCIONALMENTE EN FORMA DE MONOHIDRATO E IMIPENEM Y CILASTATINA; NATIONAL AUTHORISATION NUMBER: EU/1/19/1420; DATE OF AUTHORISATION: 20200213; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1420; DATE OF FIRST AUTHORISATION IN EEA: 20200213
1620113	CA 2015 00045	Denmark		PRODUCT NAME: IVERMECTIN, 22, 23-DIHYDROAVERMECTINB1A + 22,23-DIHRODROAVERMECTIN B1B FOR USE IN THE TREATMNET OF RESACEA; NAT. REG. NO/DATE: 54123 20150422; FIRST REG. NO/DATE: MT MA 117/01101 20150402

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Merck
• Merck And Co Inc
• Merck Kgaa
• Merck Sharp Dohme

Merck & Co.: Market Position, Strengths, and Strategic Insights

Last updated: February 19, 2026

Merck & Co. maintains a robust market position driven by key oncology and vaccine franchises, supported by a strong R&D pipeline and strategic acquisitions. The company faces competition across its therapeutic areas from major pharmaceutical players with similar pipeline ambitions and established market presences. Merck's strategy focuses on leveraging its existing strengths while pursuing innovative solutions in areas of high unmet medical need.

What is Merck's Current Market Position?

Merck & Co. (NYSE: MRK), headquartered in Rahway, New Jersey, operates as a global biopharmaceutical leader. Its market position is defined by significant revenue streams from its oncology and vaccines segments, alongside contributions from its cardiometabolic and animal health divisions.

In 2023, Merck reported total revenue of $60.1 billion. The oncology segment, primarily driven by Keytruda (pembrolizumab), accounted for $21.2 billion in sales, representing 35% of total revenue. The vaccines segment, led by Gardasil/Gardasil 9 (human papillomavirus vaccine), generated $7.2 billion, or 12% of revenue. The cardiometabolic franchise, including Januvia (sitagliptin) and its combination products, contributed $5.3 billion (9%). Merck Animal Health revenue was $6.5 billion (11%). The remaining revenue stems from other pharmaceutical products [1].

Merck holds a leading position in the global oncology market, particularly in the immuno-oncology space with Keytruda. Keytruda's broad label indications across numerous cancer types contribute to its market dominance. The company also maintains a strong global presence in the vaccine market, with Gardasil and Gardasil 9 holding significant market share for HPV prevention.

What are Merck's Key Strengths?

Merck's core strengths lie in its established leadership in oncology, a robust vaccine portfolio, a deep R&D pipeline, and a history of successful strategic partnerships and acquisitions.

Oncology Dominance:

• Keytruda (pembrolizumab): This PD-1 inhibitor is Merck's flagship product. It is approved for more than 30 indications in the United States and over 100 indications globally. Keytruda is a primary driver of Merck's revenue growth and is a standard-of-care in multiple cancer types, including melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma [2]. In 2023, Keytruda sales were $21.2 billion [1].
• Pipeline Expansion: Merck continues to invest in expanding Keytruda's utility through combination therapies and new indications. The company has ongoing clinical trials exploring Keytruda in neoadjuvant and adjuvant settings, as well as in combination with other novel agents [3].

Vaccines Leadership:

• Gardasil/Gardasil 9: These vaccines protect against human papillomavirus (HPV) infections that can lead to various cancers. Gardasil 9 is the most recent iteration, offering broader protection. Merck has focused on increasing global vaccination rates for HPV. In 2023, Gardasil/Gardasil 9 sales were $7.2 billion [1].
• Pediatric Vaccines: Merck also markets vaccines for pediatric use, contributing to its broader public health impact and revenue diversification.

R&D Pipeline and Innovation:

• Oncology Focus: Merck's R&D efforts remain heavily weighted towards oncology. The pipeline includes novel immuno-oncology agents, targeted therapies, and therapeutic vaccines [3].
• Other Therapeutic Areas: The company also pursues R&D in cardiovascular diseases, infectious diseases, and diabetes, although these areas receive less R&D investment compared to oncology.
• Genetics and Precision Medicine: Merck is increasingly integrating genomic information and precision medicine approaches into its drug discovery and development.

Strategic Partnerships and Acquisitions:

• Collaborations: Merck has a history of engaging in strategic collaborations with academic institutions and smaller biotech companies to access novel science and technology.
• Acquisitions: The acquisition of Prometheus Biosciences in 2023 for approximately $10.8 billion significantly bolsters Merck's pipeline in immunology, particularly with its investigational autoimmune disease drug, teprahibart (MK-7030) [4]. This move signals a strategic expansion beyond oncology.

What are Merck's Primary Therapeutic Areas and Key Products?

Merck's operations are structured around several key therapeutic areas, with oncology and vaccines representing the largest revenue generators.

Oncology:

• Keytruda (pembrolizumab): Monotherapy and combination therapy for various solid tumors and hematologic malignancies.
• Welireg (belzutifan): A HIF-2α inhibitor for von Hippel-Lindau (VHL) disease-associated tumors [5].
• Lynparza (olaparib): A PARP inhibitor (co-developed with AstraZeneca) for certain ovarian, breast, prostate, and pancreatic cancers [6].
• Tukysa (tucatinib): A tyrosine kinase inhibitor for HER2-positive breast cancer and potentially other HER2-positive cancers (licensed from Seagen) [7].

Vaccines:

• Gardasil/Gardasil 9: Vaccines against HPV types responsible for cervical, anal, oropharyngeal, and other cancers.
• Bexsero: A vaccine against serogroup B meningococcal disease.
• ProQuad/MMR-II/Varivax: Combination and individual vaccines for measles, mumps, rubella, and varicella [1, 8].

Cardiometabolic:

• Januvia (sitagliptin): A DPP-4 inhibitor for type 2 diabetes.
• Janumet (sitagliptin and metformin): Combination therapy for type 2 diabetes.
• Bridion (sugammadex): Used to reverse neuromuscular blockade [1].

Other:

• Noxafil (posaconazole): An antifungal medication.
• Remicade (infliximab): An anti-TNF biologic for inflammatory diseases (in-licensed) [1].

Who are Merck's Major Competitors?

Merck faces significant competition across its therapeutic portfolios from a range of global pharmaceutical and biotechnology companies.

Oncology Competitors:

• Roche: Competes with Keytruda through its PD-L1 inhibitor Tecentriq (atezolizumab) and broad portfolio of targeted therapies and diagnostics.
• Bristol Myers Squibb: Offers Opdivo (nivolumab), another PD-1 inhibitor, and a strong pipeline in immuno-oncology and cell therapy.
• Pfizer: Competes with targeted therapies like Ibrance (palbociclib) for breast cancer and has a growing immuno-oncology pipeline.
• AstraZeneca: Co-develops Lynparza with Merck and offers Imfinzi (durvalumab), a PD-L1 inhibitor, and other oncology assets.
• Eli Lilly and Company: Competes with various oncology treatments and is developing novel immuno-oncology agents.
• Novartis: Offers targeted therapies and is advancing its CAR-T cell therapy programs.

Vaccine Competitors:

• GlaxoSmithKline (GSK): A major competitor in the vaccine market with a broad portfolio, including HPV vaccines and flu vaccines.
• Pfizer: Competes in pediatric vaccines and has a pneumococcal conjugate vaccine.
• Sanofi: Offers a range of vaccines, including influenza and meningococcal vaccines.

Cardiometabolic Competitors:

• Eli Lilly and Company: Competes with its GLP-1 receptor agonists (e.g., Trulicity, Mounjaro) for type 2 diabetes.
• Novo Nordisk: A dominant player in diabetes care with a strong portfolio of insulin and GLP-1 receptor agonists.
• Janssen (Johnson & Johnson): Offers SGLT2 inhibitors and other diabetes treatments.

Immunology Competitors (post-Prometheus acquisition):

• AbbVie: Competes with Humira (adalimumab) and Skyrizi (risankizumab) in inflammatory diseases.
• Janssen (Johnson & Johnson): Offers Stelara (ustekinumab).
• Amgen: Competes with Enbrel (etanercept) and other biologics.

What are Merck's Strategic Priorities and Future Outlook?

Merck's strategic priorities center on maximizing the value of its existing blockbuster products, advancing its R&D pipeline, and exploring strategic business development opportunities.

Key Strategic Priorities:

• Oncology Leadership: Continued investment in Keytruda's lifecycle management, including label expansions, combination therapies, and development in earlier lines of treatment. The company aims to solidify its position as a leader in immuno-oncology.
• Vaccine Growth: Expanding access and uptake of Gardasil 9 globally. Merck also seeks to advance its pipeline of novel vaccines for infectious diseases.
• Diversification through Immunology: The acquisition of Prometheus Biosciences signals a strategic move to build a significant presence in the immunology market, targeting chronic inflammatory conditions like inflammatory bowel disease.
• R&D Pipeline Advancement: Progressing a diverse pipeline in oncology, immunology, and other selected therapeutic areas. Merck prioritizes novel modalities and targets with high unmet medical need.
• Operational Excellence: Focusing on efficient manufacturing and supply chain management to support global product demand.

Future Outlook: Merck's future outlook is closely tied to the continued success of Keytruda and Gardasil 9, along with the successful integration and development of its immunology assets. The company anticipates sustained growth driven by its oncology franchise. However, patent expiries for key products in the mid-to-late 2020s and beyond present a significant challenge, necessitating the successful commercialization of pipeline assets.

The competitive landscape in oncology remains intense, requiring continuous innovation and differentiation. The immunology market, while offering significant growth potential, is also highly competitive. Merck's ability to execute on its R&D and business development strategies will be critical to its long-term market performance.

Key Takeaways

• Merck & Co. holds a strong market position, primarily driven by its oncology (Keytruda) and vaccine (Gardasil) franchises, which generated $21.2 billion and $7.2 billion respectively in 2023.
• Key strengths include a dominant oncology portfolio, a leading vaccine franchise, a robust R&D pipeline, and a strategic approach to acquisitions, exemplified by the Prometheus Biosciences deal to expand into immunology.
• The company faces intense competition in oncology from major players like Roche, Bristol Myers Squibb, and Pfizer, and in vaccines from GSK and Sanofi.
• Strategic priorities focus on maximizing Keytruda's lifecycle, growing vaccine sales, building a significant immunology business, and advancing its R&D pipeline.
• Merck's future growth is contingent on the sustained performance of its core franchises and the successful commercialization of pipeline assets, particularly in light of impending patent expirations.

FAQs

1. What is Merck's primary strategy for addressing patent cliffs on its blockbuster drugs? Merck's strategy involves maximizing the lifecycle of its current blockbuster drugs through label expansions and combination therapies, while concurrently investing heavily in R&D and pursuing strategic business development, such as acquisitions, to bring new, innovative products to market before key patent expirations.

2. How significant is the acquisition of Prometheus Biosciences to Merck's long-term strategy? The acquisition of Prometheus Biosciences for approximately $10.8 billion is a significant strategic move to establish a strong presence in the immunology market. It provides Merck with teprahibart (MK-7030), a promising investigational therapy for autoimmune diseases, aiming to diversify its revenue base beyond oncology.

3. What are the main therapeutic areas Merck is targeting with its R&D pipeline beyond oncology and immunology? While oncology and immunology are primary focuses, Merck also invests in R&D for cardiovascular diseases and infectious diseases. The company selectively pursues opportunities in other areas where it sees potential for significant therapeutic impact.

4. What is Merck's market share in the global HPV vaccine market? Merck's Gardasil and Gardasil 9 vaccines hold a substantial share of the global HPV vaccine market. While exact market share figures fluctuate, they are a leading product in this segment, driven by broad approvals and global vaccination programs.

5. How is Merck leveraging data and artificial intelligence in its drug discovery and development processes? Merck is increasingly integrating data analytics and artificial intelligence into its R&D operations. This includes using AI for target identification, optimizing clinical trial design, and accelerating drug discovery and development timelines.

Citations

[1] Merck & Co., Inc. (2024). 2023 Annual Report. Retrieved from https://www.merck.com/investors/financial-reports/annual-reports/ [2] Keytruda prescribing information. (n.d.). Retrieved from the FDA website. [3] Merck R&D Pipeline. (n.d.). Retrieved from the Merck corporate website. [4] Merck completes acquisition of Prometheus Biosciences. (2023, October 18). Merck News Release. Retrieved from https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences/ [5] Welireg prescribing information. (n.d.). Retrieved from the FDA website. [6] Lynparza prescribing information. (n.d.). Retrieved from the FDA website. [7] Tukysa prescribing information. (n.d.). Retrieved from the FDA website. [8] Merck Vaccines Information. (n.d.). Retrieved from the Merck corporate website.